Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease-Reference-Cited by-同舟云学术

Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease

Published:2016-05 Issue:20 Volume:67 Page:2442-2444
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Kooiman Judith,van der Hulle Tom,Maas Hugo,Wiebe Sabrina,Formella Stephan,Clemens Andreas,van Buren Marjolijn,Janssen Martien,Rabelink Ton J.,Huisman Menno V.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference3 articles.

1. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment;Hariharan;J Clin Pharmacol,2012

2. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation;Lehr;J Clin Pharmacol,2012

3. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial;Liesenfeld;J Thrombosis Haemostasis,2011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real World Outcomes of Direct Oral Anticoagulant in End Stage Kidney Disease on Dialysis;Journal of Korean Dialysis Access;2024-05-25

2. Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists;Research and Practice in Thrombosis and Haemostasis;2024-01

3. Anticoagulation in Patients with Chronic Kidney Disease;American Journal of Nephrology;2023-11-30

4. Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency;Advances in Therapy;2023-08-18

5. Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant;IJC Heart & Vasculature;2022-12